A Japanese, Multicenter, Open-label, Phase 3 Study to Investigate the Safety and Efficacy of Gadobutrol for Contrast-enhanced MR Imaging of the Central Nervous System

• TANAKA Akio

  Department of Radiology, Ota Memorial Hospital

• MASUMOTO Tomohiko

  Department of Radiology, University of Tsukuba

• YAMADA Haruyasu

  Department of Radiology, Nihon University School of Medicine

• KURAUCHI Masayo

  Clinical Development Specialty Medicine, Bayer Yakuhin

• BREUER Josy

  Global Medical and Clinical Affairs Radiology, Bayer Pharma AG

抄録

Purpose: Gadobutrol 1.0 M is macrocyclic gadolinium-based contrast agent for magnetic resonance imaging (MRI). This multicenter, open-label, phase 3 study aimed to investigate the efficacy and safety of gadobutrol-enhanced versus unenhanced MRI in the visualization and diagnosis of central nervous system (CNS) lesions in Japanese patients.<br> Methods: A total of 223 patients referred for contrast-enhanced MRI of the CNS underwent unenhanced and gadobutrol-enhanced (0.1 mmol/kg body weight) MRI. The unenhanced and combined (unenhanced and enhanced) images were evaluated by three independent readers in a blinded manner for degree of contrast enhancement, border delineation, internal morphology, and number of detected lesions (primary variables), and for primary diagnosis and diagnostic confidence. Final clinical diagnoses were established by an independent truth committee consisting of two neurosurgeons. Sensitivity, specificity, and accuracy were calculated for the detection of malignancy and the preciseness of diagnoses (secondary variables) by comparing the results obtained by the blinded readers and the truth committee.<br>Results: Gadobutrol enhancement significantly improved three visualization parameters in MR images: contrast enhancement, border delineation, and internal morphology (P < 0.0001). Non-inferiority was achieved for mean number of lesions detected. Gadobutrol-enhanced imaging provided significant improvements in sensitivity and accuracy for the detection of malignant disease with no loss in specificity, and also improvements in accuracy of exact match diagnosis and diagnostic confidence. Drug-related adverse events were reported in 6 out of 223 patients (2.7%); all were non-serious.<br>Conclusion: Gadobutrol is an effective and well-tolerated contrast agent for MR imaging of the CNS.

収録刊行物

• Magnetic Resonance in Medical Sciences

  Magnetic Resonance in Medical Sciences 15 (2), 227-236, 2016

  日本磁気共鳴医学会

キーワード

• phase 3 clinical study
• gadobutrol
• contrast-enhanced MRI
• central nervous system

詳細情報

• CRID: 1390001205196161920
• NII論文ID: 130005144170
• NII書誌ID: AA11648770
• DOI: 10.2463/mrms.mp.2015-0083
• ISSN: 18802206
• ISSN: 13473182
• HANDLE: 2241/00143755
• PubMed: 26687097
• Web Site: https://tsukuba.repo.nii.ac.jp/records/39088
• Web Site: https://www.jstage.jst.go.jp/article/mrms/15/2/15_mp.2015-0083/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016264713
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可